Quantitative serum nuclear magnetic resonance metabolomics in cardiovascular epidemiology and genetics

Circulation: Cardiovascular Genetics

Volumn 8, Issue 1, 2015, Pages 192-206

  Soininen, Pasi ^a,b   Kangas, Antti J ^a   Würtz, Peter ^a   Suna, Teemu ^a   Ala Korpela, Mika ^a,b,c,d  

^a UNIVERSITY OF OULU   (Finland)

^b UNIVERSITY OF EASTERN FINLAND   (Finland)

^c OULU UNIVERSITY HOSPITAL   (Finland)

^d UNIVERSITY OF BRISTOL   (United Kingdom)

Author keywords

Genetics; Lipoprotein; metabolism; Metabolomics; risk assessment

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN B; BIOLOGICAL MARKER; CHOLESTEROL; FATTY ACID; TRIACYLGLYCEROL;

ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; DIABETIC NEPHROPATHY; GENETICS; HIGH THROUGHPUT SCREENING; HUMAN; METABOLOMICS; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; NUCLEAR MAGNETIC RESONANCE IMAGING; PHYSICAL ACTIVITY; PLEIOTROPY; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; SERUM; BLOOD; CARDIOVASCULAR DISEASES; PROCEDURES; RADIOGRAPHY;

CARDIOVASCULAR DISEASES; HUMANS; MAGNETIC RESONANCE IMAGING; METABOLOMICS;

EID: 84924533418     PISSN: 1942325X     EISSN: 19423268     Source Type: Journal    
DOI: 10.1161/CIRCGENETICS.114.000216     Document Type: Article

References (95)

1. Ala-Korpela M. Potential role of body fluid 1H NMR metabonomics as a prognostic and diagnostic tool. Expert Rev Mol Diagn. 2007;7:761-773. doi: 10.1586/14737159.7.6.761.
2. Ala-Korpela M. Critical evaluation of 1H NMR metabonomics of serum as a methodology for disease risk assessment and diagnostics. Clin Chem Lab Med. 2008;46:27-42. doi: 10.1515/CCLM.2008.006.
3. Ala-Korpela M, Kangas AJ, Soininen P. Quantitative high-throughput metabolomics: a new era in epidemiology and genetics. Genome Med. 2012;4:36. doi: 10.1186/gm335.
4. Soininen P, Kangas AJ, Würtz P, Tukiainen T, Tynkkynen T, Laatikainen R, et al. High-throughput serum NMR metabonomics for cost-effective holistic studies on systemic metabolism. Analyst. 2009;134:1781-1785. doi: 10.1039/b910205a.
5. Tukiainen T, Tynkkynen T, Mäkinen VP, Jylänki P, Kangas A, Hokkanen J, et al. A multi-metabolite analysis of serum by 1H NMR spectroscopy: early systemic signs of Alzheimer's disease. Biochem Biophys Res Commun. 2008;375:356-361. doi: 10.1016/j.bbrc.2008.08.007.
6. Kettunen J, Tukiainen T, Sarin AP, Ortega-Alonso A, Tikkanen E, Lyytikäinen LP, et al. Genome-wide association study identifies multiple loci influencing human serum metabolite levels. Nat Genet. 2012;44:269-276. doi: 10.1038/ng.1073.
7. Dunn WB, Broadhurst DI, Atherton HJ, Goodacre R, Griffin JL. Systems level studies of mammalian metabolomes: the roles of mass spectrometry and nuclear magnetic resonance spectroscopy. Chem Soc Rev. 2011;40:387-426. doi: 10.1039/b906712b.
8. Mäkinen VP, Soininen P, Forsblom C, Parkkonen M, Ingman P, Kaski K, et al; FinnDiane Study Group. 1H NMR metabonomics approach to the disease continuum of diabetic complications and premature death. Mol Syst Biol. 2008;4:167. doi: 10.1038/msb4100205.
9. Holmes E, Wilson ID, Nicholson JK. Metabolic phenotyping in health and disease. Cell. 2008;134:714-717. doi: 10.1016/j.cell.2008.08.026.
10. Inouye M, Kettunen J, Soininen P, Silander K, Ripatti S, Kumpula LS, et al. Metabonomic, transcriptomic, and genomic variation of a population cohort. Mol Syst Biol. 2010;6:441. doi: 10.1038/msb.2010.93.
11. Ala-Korpela M, Kangas AJ, Inouye M. Genome-wide association studies and systems biology: together at last. Trends Genet. 2011;27:493-498. doi: 10.1016/j.tig.2011.09.002.
12. Suhre K, Wallaschofski H, Raffler J, Friedrich N, Haring R, Michael K, et al. A genome-wide association study of metabolic traits in human urine. Nat Genet. 2011;43:565-569. doi: 10.1038/ng.837.
13. Nicholson G, Rantalainen M, Li JV, Maher AD, Malmodin D, Ahmadi KR, et al; MolPAGE Consortium. A genome-wide metabolic QTL analysis in Europeans implicates two loci shaped by recent positive selection. PLoS Genet. 2011;7:e1002270. doi: 10.1371/journal.pgen.1002270.
14. Nicholson G, Rantalainen M, Maher AD, Li JV, Malmodin D, Ahmadi KR, et al. Human metabolic profiles are stably controlled by genetic and environmental variation. Mol Syst Biol. 2011;7:525. doi: 10.1038/msb.2011.57.
15. Chambers JC, Zhang W, Sehmi J, Li X, Wass MN, Van der Harst P, et al; Alcohol Genome-wide Association (AlcGen) Consortium; Diabetes Genetics Replication and Meta-analyses (DIAGRAM+) Study; Genetic Investigation of Anthropometric Traits (GIANT) Consortium; Global Lipids Genetics Consortium; Genetics of Liver Disease (GOLD) Consortium; International Consortium for Blood Pressure (ICBP-GWAS); Meta-analyses of Glucose and Insulin-Related Traits Consortium (MAGIC). Genome-wide association study identifies loci influencing concentrations of liver enzymes in plasma. Nat Genet. 2011;43:1131-1138. doi: 10.1038/ng.970.
16. Stančáková A, Paananen J, Soininen P, Kangas AJ, Bonnycastle LL, Morken MA, et al. Effects of 34 risk loci for type 2 diabetes or hyperglycemia on lipoprotein subclasses and their composition in 6,580 nondiabetic Finnish men. Diabetes. 2011;60:1608-1616. doi: 10.2337/db10-1655.
17. Wang TJ, Larson MG, Vasan RS, Cheng S, Rhee EP, McCabe E, et al. Metabolite profiles and the risk of developing diabetes. Nat Med. 2011;17:448-453. doi: 10.1038/nm.2307.
18. Rhee EP, Cheng S, Larson MG, Walford GA, Lewis GD, McCabe E, et al. Lipid profiling identifies a triacylglycerol signature of insulin resistance and improves diabetes prediction in humans. J Clin Invest. 2011;121:1402-1411. doi: 10.1172/JCI44442.
19. Würtz P, Raiko JR, Magnussen CG, Soininen P, Kangas AJ, Tynkkynen T, et al. High-throughput quantification of circulating metabolites improves prediction of subclinical atherosclerosis. Eur Heart J. 2012;33:2307-2316. doi: 10.1093/eurheartj/ehs020.
20. Würtz P, Mäkinen VP, Soininen P, Kangas AJ, Tukiainen T, Kettunen J, et al. Metabolic signatures of insulin resistance in 7,098 young adults. Diabetes. 2012;61:1372-1380. doi: 10.2337/db11-1355.
21. Tukiainen T, Kettunen J, Kangas AJ, Lyytikäinen LP, Soininen P, Sarin AP, et al. Detailed metabolic and genetic characterization reveals new associations for 30 known lipid loci. Hum Mol Genet. 2012;21:1444-1455. doi: 10.1093/hmg/ddr581.
22. Inouye M, Ripatti S, Kettunen J, Lyytikäinen LP, Oksala N, Laurila PP, et al. Novel Loci for metabolic networks and multi-tissue expression studies reveal genes for atherosclerosis. PLoS Genet. 2012;8:e1002907. doi: 10.1371/journal.pgen.1002907.
23. Würtz P, Tiainen M, Mäkinen VP, Kangas AJ, Soininen P, Saltevo J, et al. Circulating metabolite predictors of glycemia in middle-aged men and women. Diabetes Care. 2012;35:1749-1756. doi: 10.2337/dc11-1838.
24. Stančáková A, Civelek M, Saleem NK, Soininen P, Kangas AJ, Cederberg H, et al. Hyperglycemia and a common variant of GCKR are associated with the levels of eight amino acids in 9,369 Finnish men. Diabetes. 2012;61:1895-1902. doi: 10.2337/db11-1378.
25. Wang J, Stančáková A, Soininen P, Kangas AJ, Paananen J, Kuusisto J, et al. Lipoprotein subclass profiles in individuals with varying degrees of glucose tolerance: a population-based study of 9399 Finnish men. J Intern Med. 2012;272:562-572. doi: 10.1111/j.1365-2796.2012.02562.x.
26. Mäkinen VP, Kangas AJ, Soininen P, Würtz P, Groop PH, Ala-Korpela M. Metabolic phenotyping of diabetic nephropathy. Clin Pharmacol Ther. 2013;94:566-569. doi: 10.1038/clpt.2013.158.
27. Würtz P, Kangas AJ, Soininen P, Lehtimäki T, Kähönen M, Viikari JS, et al. Lipoprotein subclass profiling reveals pleiotropy in the genetic variants of lipid risk factors for coronary heart disease: a note on Mendelian randomization studies. J Am Coll Cardiol. 2013;62:1906-1908. doi: 10.1016/j.jacc.2013.07.085.
28. Kujala UM, Mäkinen VP, Heinonen I, Soininen P, Kangas AJ, Leskinen TH, et al. Long-term leisure-time physical activity and serum metabolome. Circulation. 2013;127:340-348. doi: 10.1161/CIRCULATIONAHA.112.105551.
29. Larmo PS, Kangas AJ, Soininen P, Lehtonen HM, Suomela JP, Yang B, et al. Effects of sea buckthorn and bilberry on serum metabolites differ according to baseline metabolic profiles in overweight women: a randomized crossover trial. Am J Clin Nutr. 2013;98:941-951. doi: 10.3945/ajcn.113.060590.
30. Mahendran Y, Vangipurapu J, Cederberg H, Stancáková A, Pihlajamäki J, Soininen P, et al. Association of ketone body levels with hyperglycemia and type 2 diabetes in 9,398 Finnish men. Diabetes. 2013;62:3618-3626. doi: 10.2337/db12-1363.
31. Mahendran Y, Cederberg H, Vangipurapu J, Kangas AJ, Soininen P, Kuusisto J, et al. Glycerol and fatty acids in serum predict the development of hyperglycemia and type 2 diabetes in Finnish men. Diabetes Care. 2013;36:3732-3738. doi: 10.2337/dc13-0800.
32. Fischer K, Kettunen J, Würtz P, Haller T, Havulinna AS, Kangas AJ, et al. Biomarker profiling by nuclear magnetic resonance spectroscopy for the prediction of all-cause mortality: an observational study of 17,345 persons. PLoS Med. 2014;11:e1001606. doi: 10.1371/journal.pmed.1001606.
33. Auro K, Joensuu A, Fischer K, Kettunen J, Salo P, Mattsson H, et al. A metabolic view on menopause and ageing. Nat Commun. 2014;5:4708. doi: 10.1038/ncomms5708.
34. Würtz P, Soininen P, Kangas AJ, Mäkinen VP, Groop PH, Savolainen MJ, et al. Characterization of systemic metabolic phenotypes associated with subclinical atherosclerosis. Mol Biosyst. 2011;7:385-393. doi: 10.1039/c0mb00066c.
35. Würtz P, Soininen P, Kangas AJ, Rönnemaa T, Lehtimäki T, Kähönen M, et al. Branched-chain and aromatic amino acids are predictors of insulin resistance in young adults. Diabetes Care. 2013;36:648-655. doi: 10.2337/dc12-0895.
36. Mäkinen VP, Soininen P, Kangas AJ, Forsblom C, Tolonen N, Thorn LM, et al Finnish Diabetic Nephropathy Study Group. Triglyceride-cholesterol imbalance across lipoprotein subclasses predicts diabetic kidney disease and mortality in type 1 diabetes: the FinnDiane Study. J Intern Med. 2013;273:383-395. doi: 10.1111/joim.12026.
37. Al-Hussaini A, Tan T, Sehmi J, Elliott P, Ala-Korpela M, Kooner JS, et al. Abstract P020: 1H NMR metabonomic profiling identifies novel biomarkers for cardiovascular mortality. Circulation. 2012;125:AP020.
38. Vangipurapu J, Stančáková A, Kuulasmaa T, Soininen P, Kangas AJ, Ala-Korpela M, et al. Association between liver insulin resistance and cardiovascular risk factors. J Intern Med. 2012;272:402-408. doi: 10.1111/j.1365-2796.2012.02540.x.
39. Valcárcel B, Ebbels TMD, Kangas AJ, Soininen P, Elliot P, Ala-Korpela M, et al. Genome metabolome integrated network analysis to uncover connections between genetic variants and complex traits: an application to obesity. J R Soc Interface. 2014;11:20130908. doi: 10.1098/rsif.2013.0908.
40. Mallol R, Rodriguez MA, Brezmes J, Masana L, Correig X. Human serum/plasma lipoprotein analysis by NMR: application to the study of diabetic dyslipidemia. Prog Nucl Magn Reson Spectrosc. 2013;70:1-24. doi: 10.1016/j.pnmrs.2012.09.001.
41. Jelenkovic A, Bogl LH, Rose RJ, Kangas AJ, Soininen P, Ala-Korpela M, et al. Association between serum fatty acids and lipoprotein subclass profile in healthy young adults: exploring common genetic and environmental factors. Atherosclerosis. 2014;233:394-402. doi: 10.1016/j.atherosclerosis.2013.12.053.
42. Cheng S. Interrogating the age-old wisdom of exercise. Circulation. 2013;127:317-319. doi: 10.1161/CIRCULATIONAHA.112.155879.
43. Holmes E, Loo RL, Stamler J, Bictash M, Yap IKS, Chan Q, et al. Human metabolic phenotype diversity and its association with diet and blood pressure. Nature. 2008;453:396-400.
44. Stamler J, Brown IJ, Yap IKS, Chan Q, Wijeyesekera A, Garcia-Perez I, et al. Dietary and urinary metabonomic factors possibly accounting for higher blood pressure of black compared with white Americans: results of International Collaborative Study on macro-/micronutrients and blood pressure. Hypertension. 2013;62:1074-1080.
45. Loo RL, Coen M, Ebbels T, Cloarec O, Maibaum E, Bictash M, et al INTERMAP Research Group. Metabolic profiling and population screening of analgesic usage in nuclear magnetic resonance spectroscopy-based large-scale epidemiologic studies. Anal Chem. 2009;81:5119-5129. doi: 10.1021/ac900567e.
46. International Consortium for Blood Pressure Genome-Wide Association Studies, Ehret GB, Munroe PB, Rice KM, Bochud M, Johnson AD, et al. Genetic variants in novel pathways influence blood pressure and cardiovascular disease risk. Nature. 2011;478:103-109. doi: 10.1038/nature10405.
47. Quehenberger O, Armando AM, Brown AH, Milne SB, Myers DS, Merrill AH, et al. Lipidomics reveals a remarkable diversity of lipids in human plasma. J Lipid Res. 2010;51:3299-3305. doi: 10.1194/jlr.M009449.
48. Chen R, Mias GI, Li-Pook-Than J, Jiang L, Lam HYK, Chen R, et al. Personal omics profiling reveals dynamic molecular and medical phenotypes. Cell. 2012;148:1293-1307. doi: 10.1016/j.cell.2012.02.009.
49. Suhre K, Shin SY, Petersen AK, Mohney RP, Meredith D, Wägele B, et al CARDIoGRAM. Human metabolic individuality in biomedical and pharmaceutical research. Nature. 2011;477:54-60. doi: 10.1038/nature10354.
50. Ala-Korpela M, Sipola P, Kaski K. Characterization and molecular detection of atherothrombosis by magnetic resonance-potential tools for individual risk assessment and diagnostics. Ann Med. 2006;38:322-336. doi: 10.1080/07853890600862418.
51. Quehenberger O, Dennis EA. The human plasma lipidome. N Engl J Med. 2011;365:1812-1823. doi: 10.1056/NEJMra1104901.
52. Psychogios N, Hau DD, Peng J, Guo AC, Mandal R, Bouatra S, et al. The human serum metabolome. PLoS One. 2011;6:e16957. doi: 10.1371/journal.pone.0016957.
53. Ala-Korpela M. 1H NMR spectroscopy of human blood plasma. Prog Nucl Magn Reson Spectrosc. 1995;27:475-554.
54. Study on NMR based lipoprotein subclass analysis. Bruker. http://www.bruker.com/fileadmin/user-upload/8-PDF-Docs/MagneticResonance/NMR/brochures/lipo-analysis-apps.pdf. Accessed October 5, 2014.
55. Kaess B, Fischer M, Baessler A, Stark K, Huber F, Kremer W, et al. The lipoprotein subfraction profile: heritability and identification of quantitative trait loci. J Lipid Res. 2008;49:715-723. doi: 10.1194/jlr.M700338-JLR200.
56. Ala-Korpela M, Soininen P, Savolainen MJ. Letter by Ala-Korpela et al regarding article, "Lipoprotein particle profiles by nuclear magnetic resonance compared with standard lipids and apolipoproteins in predicting incident cardiovascular disease in women". Circulation. 2009;120:e149; author reply e150. doi: 10.1161/CIRCULATIONAHA.109.864124.
57. Rosenson RS, Underberg JA. Systematic review: Evaluating the effect of lipid-lowering therapy on lipoprotein and lipid values. Cardiovasc Drugs Ther. 2013;27:465-479. doi: 10.1007/s10557-013-6477-6.
58. Mackey RH, Greenland P, Goff DC Jr, Lloyd-Jones D, Sibley CT, Mora S. High-density lipoprotein cholesterol and particle concentrations, carotid atherosclerosis, and coronary events: MESA (multi-ethnic study of atherosclerosis). J Am Coll Cardiol. 2012;60:508-516. doi: 10.1016/j.jacc.2012.03.060.
59. Matyus SP, Braun PJ, Wolak-Dinsmore J, Jeyarajah EJ, Shalaurova I, Xu Y, et al. NMR measurement of LDL particle number using the Vantera® Clinical Analyzer. Clin Biochem. 2014;47:203-210. doi: 10.1016/j.clinbiochem.2014.07.01.
60. Mora S, Otvos JD, Rifai N, Rosenson RS, Buring JE, Ridker PM. Lipoprotein particle profiles by nuclear magnetic resonance compared with standard lipids and apolipoproteins in predicting incident cardiovascular disease in women. Circulation. 2009;119:931-939. doi: 10.1161/CIRCULATIONAHA.108.816181.
61. Madsen R, Lundstedt T, Trygg J. Chemometrics in metabolomics-a review in human disease diagnosis. Anal Chim Acta. 2010;659:23-33. doi: 10.1016/j.aca.2009.11.042.
62. Bothwell JHF, Griffin JL. An introduction to biological nuclear magnetic resonance spectroscopy. Biol Rev Camb Philos Soc. 2011;86:493-510.
63. Mihaleva VV, Korhonen SP, van Duynhoven J, Niemitz M, Vervoort J, Jacobs DM. Automated quantum mechanical total line shape fitting model for quantitative NMR-based profiling of human serum metabolites. Anal Bioanal Chem. 2014;406:3091-3102. doi: 10.1007/s00216-014-7752-5.
64. Ernst RR. Nuclear-magnetic-resonance Fourier-transform spectroscopy (Nobel Lecture). Angewandte Chemie-Int (Ed: English). 1992;31:805-823.
65. Mierisová S, Ala-Korpela M. MR spectroscopy quantitation: a review of frequency domain methods. NMR Biomed. 2001;14:247-259.
66. Vehtari A, Mäkinen VP, Soininen P, Ingman P, Mäkelä SM, Savolainen MJ, et al. A novel Bayesian approach to quantify clinical variables and to determine their spectroscopic counterparts in 1H NMR metabonomic data. BMC Bioinformatics. 2007;8 (Suppl 2):S8. doi: 10.1186/1471-2105-8-S2-S8.
67. Ala-Korpela M, Korhonen A, Keisala J, Hörkkö S, Korpi P, Ingman LP, et al. 1H NMR-based absolute quantitation of human lipoproteins and their lipid contents directly from plasma. J Lipid Res. 1994;35:2292-2304.
68. Mihaleva VV, van Schalkwijk DB, de Graaf AA, van Duynhoven J, van Dorsten FA, Vervoort J, et al. A systematic approach to obtain validated partial least square models for predicting lipoprotein subclasses from serum NMR spectra. Anal Chem. 2014;86:543-550. doi: 10.1021/ac402571z.
69. Hevonoja T, Pentikäinen MO, Hyvönen MT, Kovanen PT, Ala-Korpela M. Structure of low density lipoprotein (LDL) particles: basis for understanding molecular changes in modified LDL. Biochim Biophys Acta. 2000;1488:189-210.
70. Kumpula LS, Kumpula JM, Taskinen MR, Jauhiainen M, Kaski K, Ala-Korpela M. Reconsideration of hydrophobic lipid distributions in lipoprotein particles. Chem Phys Lipids. 2008;155:57-62. doi: 10.1016/j.chemphyslip.2008.06.003.
71. Lounila J, Ala-Korpela M, Jokisaari J, Savolainen MJ, Kesäniemi YA. Effects of orientational order and particle size on the NMR line positions of lipoproteins. Phys Rev Lett. 1994;72:4049-4052.
72. Knuiman MW, Divitini ML, Welborn TA, Bartholomew HC. Familial correlations, cohabitation effects, and heritability for cardiovascular risk factors. Ann Epidemiol. 1996;6:188-194.
73. Suhre K, Gieger C. Genetic variation in metabolic phenotypes: study designs and applications. Nat Rev Genet. 2012;13:759-769. doi: 10.1038/nrg3314.
74. Jourdan C, Petersen AK, Gieger C, Döring A, Illig T, Wang-Sattler R, et al. Body fat free mass is associated with the serum metabolite profile in a population-based study. PLoS One. 2012;7:e40009. doi: 10.1371/journal.pone.0040009.
75. Xia J, Broadhurst DI, Wilson M, Wishart DS. Translational biomarker discovery in clinical metabolomics: an introductory tutorial. Metabolomics. 2013;9:280-299. doi: 10.1007/s11306-012-0482-9.
76. Roberts LD, Gerszten RE. Toward new biomarkers of cardiometabolic diseases. Cell Metab. 2013;18:43-50. doi: 10.1016/j.cmet.2013.05.009.
77. Colhoun HM, McKeigue PM, Davey Smith G. Problems of reporting genetic associations with complex outcomes. Lancet. 2003;361:865-872.
78. Kathiresan S, Srivastava D. Genetics of human cardiovascular disease. Cell. 2012;148:1242-1257. doi: 10.1016/j.cell.2012.03.001.
79. st century: building the roads to individualized health. J Nutr. 2004;134:2729-2732.
80. Nicholson JK, Holmes E, Wilson ID. Gut microorganisms, mammalian metabolism and personalized health care. Nat Rev Microbiol. 2005;3:431-438. doi: 10.1038/nrmicro1152.
81. Plomin R, Haworth CMA, Davis OSP. Common disorders are quantitative traits. Nat Rev Genet. 2009;10:872-878.
82. Defining the scientific method [editorial]. Nature Methods. 2009;6:237-237.
83. Wang TJ. Assessing the role of circulating, genetic, and imaging biomarkers in cardiovascular risk prediction. Circulation. 2011;123:551-565. doi: 10.1161/CIRCULATIONAHA.109.912568.
84. Felig P, Marliss E, Cahill GF Jr. Plasma amino acid levels and insulin secretion in obesity. N Engl J Med. 1969;281:811-816. doi: 10.1056/NEJM196910092811503.
85. Huffman KM, Shah SH, Stevens RD, Bain JR, Muehlbauer M, Slentz CA, et al. Relationships between circulating metabolic intermediates and insulin action in overweight to obese, inactive men and women. Diabetes Care. 2009;32:1678-1683. doi: 10.2337/dc08-2075.
86. Shah SH, Kraus WE, Newgard CB. Metabolomic profiling for the identification of novel biomarkers and mechanisms related to common cardiovascular diseases: form and function. Circulation. 2012;126:1110-1120. doi: 10.1161/CIRCULATIONAHA.111.060368.
87. Magnusson M, Lewis GD, Ericson U, Orho-Melander M, Hedblad B, Engström G, et al. A diabetes-predictive amino acid score and future cardiovascular disease. Eur Heart J. 2013;34:1982-1989. doi: 10.1093/eurheartj/ehs424.
88. Smith GD, Ebrahim S. 'Mendelian randomization': can genetic epidemiology contribute to understanding environmental determinants of disease? Int J Epidemiol. 2003;32:1-22.
89. Lawlor DA, Harbord RM, Sterne JAC, Timpson N, Smith GD. Mendelian randomization: using genes as instruments for making causal inferences in epidemiology. Stat Med. 2008;27:1133-1163.
90. Solovieff N, Cotsapas C, Lee PH, Purcell SM, Smoller JW. Pleiotropy in complex traits: challenges and strategies. Nat Rev Genet. 2013;14:483-495. doi: 10.1038/nrg3461.
91. Bock JL. Analysis of serum by high-field proton nuclear magnetic resonance. Clin Chem. 1982;28:1873-1877.
92. Nicholson JK, Buckingham MJ, Sadler PJ. High resolution 1H n.m.r. studies of vertebrate blood and plasma. Biochem J. 1983;211:605-615.
93. Nicholson JK, O'Flynn MP, Sadler PJ, Macleod AF, Juul SM, Sönksen PH. Proton-nuclear-magnetic-resonance studies of serum, plasma and urine from fasting normal and diabetic subjects. Biochem J. 1984;217:365-375.
94. Bell JD, Sadler PJ, Macleod AF, Turner PR, La Ville A. 1H NMR studies of human blood plasma. Assignment of resonances for lipoproteins. FEBS Lett. 1987;219:239-243.
95. Nicholson JK, Lindon JC, Holmes E. 'Metabonomics': understanding the metabolic responses of living systems to pathophysiological stimuli via multivariate statistical analysis of biological NMR spectroscopic data. Xenobiotica. 1999;29:1181-1189. doi: 10.1080/004982599238047.